INCB 9471

Drug Profile

INCB 9471

Alternative Names: INCB009471; INCB9471

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antivirals
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 17 Mar 2008 INCB 9471 is available for licensing (http://www.incyte.com)
  • 17 Mar 2008 Incyte decides not to initiate phase IIb trials of INCB 9471 in treatment-experienced patients with HIV
  • 06 Feb 2008 Pharmacodynamics data from a phase II monotherapy trial presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top